RecruitingPHASE1, PHASE2NCT06988488
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Celgene
- Principal Investigator
- Bristol-Myers SquibbBristol-Myers Squibb
- Intervention
- Elranatamab(drug)
- Enrollment
- 62 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (22)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Yale New Haven Hospital-Smilow Cancer Center, New Haven, Connecticut, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
- Local Institution - 0026, Vancouver, British Columbia, Canada
- Local Institution - 0027, Halifax, Nova Scotia, Canada
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- Local Institution - 0030, Suzhou, Jiangsu, China
- Local Institution - 0031, Shanghai, Shanghai Municipality, China
- Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, Germany
- Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany
- Universitaetsklinikum Heidelberg, Heidelberg, Germany
- Evangelismos General Hospital of Athens, Athens, Attikí, Greece
- Alexandra General Hospital of Athens, Athens, Attikí, Greece
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06988488 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07201974Virtual Reality for Post-Stroke Gait RehabilitationMcGill University
- ENROLLING BY INVITATIONNCT07515430The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic LeukemiaSun Yat-sen University